Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufour, Jean-François, Caussy, Cyrielle, Loomba, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Recent Advances in Clinical Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497577/
https://www.ncbi.nlm.nih.gov/pubmed/32381514
http://dx.doi.org/10.1136/gutjnl-2019-319104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497577/
https://www.ncbi.nlm.nih.gov/pubmed/32381514
http://dx.doi.org/10.1136/gutjnl-2019-319104

Ejemplares similares